Literature DB >> 20497233

Neither single-marker nor haplotype analyses support an association between the dopamine transporter gene and heroin dependence in Han Chinese.

Y-W Yeh1, R-B Lu, P-L Tao, M-C Shih, W-W Lin, S-Y Huang.   

Abstract

Much evidence suggests that dysfunction of dopamine transporter-mediated dopamine transmission may be involved in the pathophysiology of substance abuse and dependence. The aim of this study was to examine whether the dopamine transporter gene (DAT1; SLC6A3) is associated with the development of heroin dependence (HD) and whether DAT1 influences personality traits in patients with HD. Polymorphisms of DAT1 were analyzed in a case-control study of 1046 Han Chinese (615 patients and 431 controls). All participants were screened using a Chinese version of the modified Schedule of Affective Disorder and Schizophrenia-Lifetime and all patients met the criteria for HD. Furthermore, a Chinese version of the Tridimensional Personality Questionnaire (TPQ) was used to assess personality traits in the patient group and examine the association between their personality traits and DAT1 polymorphisms. Of the patient group, 271 completed the TPQ. No statistically significant differences in allele or genotype frequencies of all investigated variants between HD patients and controls were observed. In haplotype analyses, four haplotype blocks of DAT1 were not associated with the development of HD. These DAT1 polymorphisms did not influence novelty seeking and harm avoidance scores in HD patients. This study suggests that the DAT1 gene may not contribute to the risk of HD and specific personality traits in HD among the Han Chinese population.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20497233     DOI: 10.1111/j.1601-183X.2010.00597.x

Source DB:  PubMed          Journal:  Genes Brain Behav        ISSN: 1601-183X            Impact factor:   3.449


  7 in total

1.  Association of dopamine receptor gene polymorphism and psychological personality traits in liability for opioid addiction.

Authors:  Nermana Mehić-Basara; Lilijana Oruč; Lejla Kapur-Pojskić; Jasmin Ramić
Journal:  Bosn J Basic Med Sci       Date:  2013-08       Impact factor: 3.363

2.  Novelty seeking mediates the effect of DRD3 variation on onset age of amphetamine dependence in Han Chinese population.

Authors:  Shin-Chang Kuo; Yi-Wei Yeh; Chun-Yen Chen; Chang-Chih Huang; Tien-Yu Chen; Che-Hung Yen; Chih-Sung Liang; Pei-Shen Ho; Ru-Band Lu; San-Yuan Huang
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-12-27       Impact factor: 5.270

3.  Association of catechol-O-methyltransferase gene polymorphisms with schizophrenia and negative symptoms in a Chinese population.

Authors:  Wen Jun Li; Chang Gui Kou; Yaqin Yu; Shilong Sun; Xuan Zhang; Thomas R Kosten; Xiang Yang Zhang
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-02-21       Impact factor: 3.568

4.  Relationship among methadone dose, polymorphisms of dopamine D2 receptor and tri-dimensional personality questionnaire in heroin-addicted patients.

Authors:  Min-Wei Huang; Tai-An Chiang; Pei-Yu Lo; Ching-Shan Huang
Journal:  Behav Brain Funct       Date:  2016-08-31       Impact factor: 3.759

5.  The SLC6A3 gene possibly affects susceptibility to late-onset alcohol dependence but not specific personality traits in a Han Chinese population.

Authors:  Chang-Chih Huang; Shin-Chang Kuo; Yi-Wei Yeh; Chun-Yen Chen; Che-Hung Yen; Chih-Sung Liang; Pei-Shen Ho; Ru-Band Lu; San-Yuan Huang
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

Review 6.  Advances in genetic studies of substance abuse in China.

Authors:  Yan Sun; Shiqiu Meng; Jiali Li; Jie Shi; Lin Lu
Journal:  Shanghai Arch Psychiatry       Date:  2013-08

Review 7.  Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders.

Authors:  Jamie A Burns; Danielle S Kroll; Dana E Feldman; Christopher Kure Liu; Peter Manza; Corinde E Wiers; Nora D Volkow; Gene-Jack Wang
Journal:  Front Psychiatry       Date:  2019-09-18       Impact factor: 4.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.